Biclonal Gammopathies in South Tunisia: Clinical and Biological Characteristics.


Journal

Laboratory medicine
ISSN: 1943-7730
Titre abrégé: Lab Med
Pays: England
ID NLM: 0250641

Informations de publication

Date de publication:
05 Sep 2023
Historique:
medline: 6 9 2023
pubmed: 18 2 2023
entrez: 17 2 2023
Statut: ppublish

Résumé

Biclonal gammopathies (BGs) are rare situations characterized by the production of 2 monoclonal proteins. There are no available data on BGs in North Africa. We aimed to estimate the prevalence of BGs in our population and describe their clinical and laboratory features. We conducted a 31-year retrospective study including patients with persistent double monoclonal bands based on the results of immunofixation/immunoelectrophoresis. A total of 35 patients with available clinical data (sex ratio, M/F = 1.53; mean age, 70 ± 10.87 years [range, 45-90 years]) were included. The main associated conditions were multiple myeloma (MM) (40%), BG of undetermined significance (BGUS) (34%), and lymphoproliferative diseases (23%). Only one-third of the patients had 2 monoclonal spikes on serum protein electrophoresis. The most common paraprotein combinations were immunoglobulin (Ig)G-IgG (25%) and IgG-IgA (23%) with different light chains in one-half of the cases. The mean follow-up was 25.6 months (median, 12 months). No BGUS evolved into a malignant disease. BGs are rare in clinical laboratory routine but must be accurately identified by the pathologist. Our cohort is characterized by a high prevalence of BGUS compared with MM.

Identifiants

pubmed: 36799924
pii: 7044682
doi: 10.1093/labmed/lmac153
doi:

Substances chimiques

Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464-468

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ameni Jerbi (A)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Hend Hachicha (H)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Aida Charfi (A)

Histocompatibility Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Faten Kallel (F)

Hematology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Sawsan Feki (S)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Mourad Ben Ayed (M)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Faten Ayadi (F)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Rim Akrout (R)

Rheumatology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Faten Frikha (F)

Internal Medicine Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Ali Amouri (A)

Gastro-enterology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Khaoula Kammoun (K)

Nephrology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Moez Mdhaffar (M)

Hematology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Mohamed Ben Hmida (M)

Nephrology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Nabil Tahri (N)

Gastro-enterology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Zouheir Bahloul (Z)

Internal Medicine Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Sofien Baklouti (S)

Rheumatology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Moez Elloumi (M)

Hematology Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia.

Hatem Masmoudi (H)

Immunology Department, Habib Bourguiba, University Hospital, University of Sfax, Sfax, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH